AAIPharma strengthens team with two
A US-based global provider of drug development services has made two appointments.
A US-based global provider of drug development services has made two appointments.
Andreas Dreps, senior vice president of global clinical development services at AAIPharma - a global drug development services company.
Meanwhile, Ralf Wolter, is appointed the new vice president clinical of operations of Europe. He will report to Dreps.
Dreps has more than 15 years of drug development experience including, most recently, leading the oncology therapeutic area for ICON, a large, global contract research organisation (CRO).
Wolter has over 12 years of clinical research experience, including early clinical development, trial management, project management, training and business development.
Speaking about the appointments, Ludo Reynders, ceo of AAI Pharma, said: "We are very fortunate to add Andreas to the leadership team of the company.
"His vast drug development experience and track record, especially in the clinical oncology area, will be invaluable in the further development of our global clinical development business unit. As we organise our business around the customer, Andreas" scientific understanding and business acumen will provide great value to the customers and project teams we serve.
"The addition of Dr Wolter to Andreas" team augments our strong foothold in Europe and his experience enhances our ability to perform large-scale global trials in key therapeutic areas."